An audit of gastroduodenal Crohn disease: clinicopathologic features and management.
BACKGROUND
This study was undertaken to assess the clinicopathologic features and management of gastroduodenal Crohn disease.


METHODS
The medical records of 54 patients with gastroduodenal Crohn disease treated between 1958 and 1997 were reviewed.


RESULTS
Gastroduodenal Crohn disease occurred in association with disease elsewhere in 52 patients (96%). The commonest pathology was stricture (n = 41), followed by ulceration (n = 4) and duodenocutaneous fistula (n = 2). Medical treatment was initially attempted in 31 patients, of whom 12 required no surgical treatment for gastroduodenal disease. Nineteen patients required surgery for gastroduodenal obstruction or fistula despite medical treatment. Overall, 33 patients (61%) required surgery; the indication was obstruction in 30, duodenocutaneous fistula in 2, and bleeding in 1. There was one postoperative death because of persistent bleeding and intraabdominal sepsis after oversewing of a bleeding ulcer. In obstructive disease 16 patients were treated by bypass surgery, 10 by strictureplasty, and 4 by gastrectomy. After surgery for obstructive disease anastomotic leak developed in three patients, and persistent gastric outlet obstruction was seen in six patients. In the long term 11 patients required reoperation for anastomotic obstruction (n = 9) or stomal ulceration (n = 2). For duodenocutaneous fistula one patient underwent simple closure of fistula, and the other patient duodenojejunostomy. Both of these patients developed an intra-abdominal abscess without evidence of leak. There has been no fistula recurrence.


CONCLUSIONS
Gastroduodenal Crohn disease is a complex and difficult problem that is associated with serious complications and need for reoperation.
Yamamoto
T
T
University Dept. of Surgery, Queen Elizabeth Hospital, Edgbaston, Birmingham, UK.
Allan
R N
RN
Keighley
M R
MR
D000293:Adolescent; D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D002648:Child; D003251:Constriction, Pathologic; D003424:Crohn Disease / Q000175:diagnosis* / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*; D004380:Duodenal Obstruction; D004386:Duodenum / Q000473:pathology; D016099:Endoscopy, Gastrointestinal; D005260:Female; D005500:Follow-Up Studies; D005756:Gastritis / Q000175:diagnosis* / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007412:Intestinal Fistula; D008297:Male; D019804:Mesalamine / Q000627:therapeutic use; D008875:Middle Aged; D010437:Peptic Ulcer; D011183:Postoperative Complications; D012189:Retrospective Studies; D013270:Stomach / Q000473:pathology; D006113:United Kingdom
D000894:Anti-Inflammatory Agents, Non-Steroidal; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D019804:Mesalamine